These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 872149)

  • 1. Adriamycin cardiac toxicity: a different hypothesis.
    Byfield JE
    Cancer Treat Rep; 1977; 61(3):497-8. PubMed ID: 872149
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cardiotoxicity due to prolonged administration of THP (2"R-4'-O-tetrahydropyranyl-adriamycin)].
    Suzuki M; Hirono M; Majima H
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1993-9. PubMed ID: 9350248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
    Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
    Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography.
    Gillings S; Johnson J; Fulmer A; Hauck M
    Vet Ther; 2009; 10(1-2):46-58. PubMed ID: 19742448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin.
    Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32, and aclacinomycin.
    Dantchev D; Slioussartchouk V; Paintrand M; Hayat M; Bourut C; Mathé G
    Cancer Treat Rep; 1979 May; 63(5):875-88. PubMed ID: 455329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac safety of liposomal anthracyclines.
    Batist G
    Cardiovasc Toxicol; 2007; 7(2):72-4. PubMed ID: 17652807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?
    Theodoulou M; Hudis C
    Cancer; 2004 May; 100(10):2052-63. PubMed ID: 15139046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preoperative intra-arterial chemotherapy with THP-ADR for locally advanced breast cancer].
    Mukai S; Fujisaki T; Sato N
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1542-5. PubMed ID: 7574754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
    Giri SN; Al-Bayati MA; Du X; Schelegle E; Mohr FC; Margolin SB
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):141-50. PubMed ID: 14564477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adriamycin-induced myocardial toxicity: new solutions for an old problem?
    Outomuro D; Grana DR; Azzato F; Milei J
    Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.
    Jones WG; Mattsson W
    Cancer Treat Rep; 1984 Apr; 68(4):675-7. PubMed ID: 6585271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer.
    Guldner L; Haddy N; Pein F; Diallo I; Shamsaldin A; Dahan M; Lebidois J; Merlet P; Villain E; Sidi D; Sakiroglu O; Hartmann O; Leftakopoulos D; de Vathaire F
    Radiother Oncol; 2006 Oct; 81(1):47-56. PubMed ID: 16989913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
    Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M
    J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurohormonal, hemodynamic, and electrocardiographic evaluations of healthy dogs receiving long-term administration of doxorubicin.
    Alves de Souza RC; Camacho AA
    Am J Vet Res; 2006 Aug; 67(8):1319-25. PubMed ID: 16881842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity associated with 4'-deoxydoxorubicin.
    Blayney D
    Cancer Treat Rep; 1986 Mar; 70(3):433. PubMed ID: 3955560
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prevention of cardiotoxic effects of anthracyclines in oncopediatric praxis].
    Safonova SA; Gershanovich ML; Punanov IuA
    Vopr Onkol; 2006; 52(5):590-2. PubMed ID: 17168373
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiotoxicity of doxorubicin and other anthracycline derivatives.
    Jain D
    J Nucl Cardiol; 2000; 7(1):53-62. PubMed ID: 10698235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.